Short answer
Tevogen Bio Holdings Inc. (TVGN) filed its Q1 2026 10-Q quarterly report on May 15, 2026 for the quarter ended Mar 31, 2026.
Q1 2026 key financials · XBRL
- Net income
- −$5M
- +47.5% YoY
- EPS (diluted)
- −$1.61
- −2200.0% YoY
Source: XBRL data from the Tevogen Bio Holdings Inc. (TVGN) Q1 2026 10-Q on SEC EDGAR. USD.
Tevogen Bio Holdings Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY; no products commercialized
- Net loss $5.4M vs $10.4M YoY; operating loss $5.4M vs $10.4M
- R&D $3.1M vs $3.2M; G&A $2.3M vs $7.2M, driven by lower stock compensation
- Cash $0.7M vs $0.6M at December 31, 2025; loan draw $6.4M with $14.0M available
- Liquidity expected for at least 12 months; R&D and commercialization expenses expected to increase significantly
Risk Factors
- New Nasdaq listing risk triggered by April 2026 notices for failing $50 million MVLS and $15 million MVPHS requirements
- Delisting exposure, with compliance deadlines October 13 and October 14, 2026
- Regulatory risk from resale-registration obligations covering 375,000 warrant shares within 30 days of May 15 closing
- Financing concentration through approximately $3.0 million Patel Family prefunded-warrant placement
- Dilution risk from warrants exercisable for 375,000 shares at $0.0001 per share
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Tevogen Bio Holdings Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.